Ligand's Two-Pronged Strike: M&A and Savvy Financing Fuel Royalty Empire

JUPITER, Fla. – August 06, 2026 – Ligand Pharmaceuticals has issued a powerful signal of business momentum, reporting second-quarter results that showcase the formidable strength of its royalty aggregation model. With royalty revenue surging 32% and a pivotal acquisition now closed, the company is not just meeting expectations but actively reshaping its future, reinforcing its status as a dominant force in biopharma financing.

The quarter was defined by a two-pronged strategic offensive: the successful integration of a transformative acquisition and a masterclass in capital management. These moves, layered on top of a booming core royalty business, prompted the company to raise the low end of its full-year adjusted earnings guidance. “Ligand delivered another strong quarter, with royalty revenue growing 32% year-over-year and continued momentum from Filspari following its FSGS approval by the FDA,” said Todd Davis, CEO of Ligand, in the company's earnings statement. The results paint a clear picture of a company executing a complex strategy with precision, turning intellectual property streams into a torrent of revenue.

The Royalty Engine Hits High Gear

At the heart of Ligand’s stellar quarter is the robust performance of its royalty portfolio. The company reported total revenues of $63.7 million, a 34% jump from the previous year, driven primarily by $48.0 million in royalties. This surge translated directly to the bottom line, with adjusted net income climbing 59% to $50.8 million, or $2.37 per diluted share, a 48% year-over-year increase.

A key driver of this growth is Filspari, a drug developed by partner Travere Therapeutics. Ligand, which holds a 9% royalty on worldwide sales, is reaping the rewards of the drug's expanding clinical and commercial success. In April, Filspari secured a landmark FDA approval for treating focal segmental glomerulosclerosis (FSGS), becoming the first and only approved medicine for the rare kidney disease. This new indication, on top of its existing use for IgA nephropathy, significantly expands its market potential. The impact is already visible, with Travere reporting a staggering 96% year-over-year growth in Filspari's U.S. net sales to $141 million. This success story exemplifies the core of Ligand's model: providing capital for late-stage development and, in return, participating in the long-term success of breakthrough therapies.

A Transformative Deal Doubles the Stakes

While organic growth was impressive, Ligand’s most significant growth signal was the closing of its acquisition of XOMA Royalty. The deal, completed just after the quarter's end, is nothing short of transformative. By adding over 120 assets to its portfolio, Ligand has more than doubled its collection of royalty streams to over 200, creating one of the industry's largest and most diversified biopharma royalty portfolios.

The acquisition immediately bolsters Ligand’s revenue streams with seven commercial products, including Roche’s blockbuster ophthalmology drug VABYSMO® and Servier’s oncology treatment OJEMDA™. More importantly, it deepens the company's pipeline with 14 late-stage development programs and over 100 earlier-stage assets, providing a foundation for future growth and mitigating the risk associated with any single product. The diversification spans new therapeutic areas and partners, including assets from Takeda's portfolio.

Financial analysts note that the acquisition is expected to be immediately accretive, projecting an addition of approximately $0.50 to adjusted earnings per share in 2026 and a substantial $1.50 in 2027. This immediate financial contribution is particularly crucial, as it helps build investor confidence following a first quarter that fell short of Wall Street expectations. The move solidifies Ligand's position alongside giants like Royalty Pharma in the competitive royalty aggregation market, demonstrating an aggressive appetite for strategic consolidation.

The Art of Capital: A $700 Million War Chest

Fueling this aggressive expansion is a remarkably shrewd financial strategy. In June, Ligand executed a $700 million convertible debt offering with a 0% interest rate. This maneuver allows the company to access a massive pool of low-cost capital without the immediate burden of interest payments, freeing up cash flow for its primary business of acquiring more royalties.

The structure of the deal is a masterclass in disciplined capital management. Ligand used a portion of the proceeds to enter into a "call spread overlay," a sophisticated hedging transaction designed to minimize potential stock dilution when the notes are eventually converted. This protects existing shareholder value, a move that institutional investors watch closely. After the hedge and a concurrent share repurchase, the company is left with approximately $700 million in deployable capital.

“Shortly after quarter-end, we closed our acquisition of XOMA Royalty... This transaction meaningfully strengthens our position as a leading biopharma royalty aggregator and, combined with our broadened portfolio, positions Ligand for a strong second half of 2026 and beyond,” Davis stated, highlighting the direct link between the company's capital strategy and its growth ambitions. This war chest ensures Ligand can continue its strategy of investing $150 million to $250 million annually in new high-value royalty assets, perpetuating its cycle of growth.

A Clearer Picture Through an Adjusted Lens

In its reporting, Ligand emphasizes adjusted earnings per share, which rose to a guided range of $9.00 to $9.50 for the full year. This non-GAAP metric strips out items like non-cash expenses, amortization of intangibles from past acquisitions, and one-time transaction costs, such as those related to the XOMA deal. While GAAP net income was a robust $48.5 million for the quarter, the adjusted figure of $50.8 million is what management believes better reflects the core operational profitability of its royalty-generating business.

Scrutinizing the reconciliation between GAAP and adjusted figures reveals the significant impact of the company's M&A activity and complex financial structure. However, the upwardly revised guidance signals strong underlying confidence from management in the company's trajectory. While royalty revenues are booming, the company's legacy Captisol sales saw a slight year-over-year decline, and operating expenses have increased, reflecting the costs of the XOMA transaction and investments in portfolio management. Investors and analysts will be watching closely for an updated five-year outlook at the company's planned Investor Day in December, which is expected to provide a more detailed roadmap for how this newly enlarged and well-funded royalty empire plans to continue its impressive momentum.